Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.
- Author:
Jaemin LEE
1
;
Sun Hong YOO
;
Won SOHN
;
Hyung Woo KIM
;
Yong Sun CHOI
;
Jung Ho WON
;
Jin Young HEO
;
Sang Jong PARK
;
Young Min PARK
Author Information
- Publication Type:Original Article
- Keywords: Chronic hepatitis B; Hepatocellular carcinoma; Obesity; Antiviral treatment
- MeSH: Adult; Antiviral Agents/*therapeutic use; Body Mass Index; Carcinoma, Hepatocellular/epidemiology/*etiology; Cohort Studies; DNA, Viral/blood; Female; Guanine/*analogs & derivatives/therapeutic use; Hepatitis B virus/genetics/isolation & purification; Hepatitis B, Chronic/complications/*drug therapy/virology; Humans; Incidence; Liver Cirrhosis/complications; Liver Neoplasms/epidemiology/*etiology; Male; Middle Aged; Obesity/*complications; Proportional Hazards Models; Retrospective Studies; Risk Factors; Viral Load
- From:Clinical and Molecular Hepatology 2016;22(3):339-349
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: This study aimed to clarify the effect of obesity on the development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients receiving antiviral treatment. METHODS: This study applied a retrospective analysis to a historical cohort in Bundang Jesaeng Hospital. In total, 102 CHB patients were treated with entecavir as an initial treatment for CHB and checked for obesity using a body composition analyzer. Hepatic steatosis was measured semiquantitatively using Hamaguchi’s scoring system in ultrasonography. Risk factors for the development of HCC were analyzed, including obesity-related factors (body mass index [BMI], waist circumference [WC], waist-to-hip ratio [WHR], visceral fat area [VFA], and hepatic steatosis). RESULTS: The median follow-up duration of the patients was 45.2 months (interquartile range: 36.0-58.3 months). The cumulative incidence rates of HCC at 1 year, 3 years, and 5 years were 0%, 5.3%, and 9.0%, respectively. Univariable analysis revealed that the risk factors for HCC development were a platelet count of <120,000 /mm² (hazard ratio [HR]=5.21, P=0.031), HBeAg negativity (HR=5.61, P=0.039), and liver cirrhosis (HR=10.26, P=0.031). Multivariable analysis showed that the significant risk factor for HCC development was liver cirrhosis (HR=9.07, P=0.042). However, none of the obesity-related risk factors were significantly associated with HCC: BMI ≥25 kg/m² (HR=0.90, P=0.894), WC ≥90 cm (HR=1.10, P=0.912), WHR ≥0.9 (HR=1.94, P=0.386), VFA ≥100 cm² (HR=1.69, P=0.495), and hepatic steatosis (HR=0.57, P=0.602). CONCLUSION: HCC development is associated with liver cirrhosis but not obesity-related factors in CHB patients receiving entecavir.
